Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 15;2014(5):CD007104.
doi: 10.1002/14651858.CD007104.pub2.

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas

Magali Lecavalier-Barsoum  1 , Harvey Quon, Bassam Abdulkarim
Affiliations

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas

Magali Lecavalier-Barsoum et al. Cochrane Database Syst Rev. .

Abstract

Background: Standard care of adjuvant treatment for anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) is not yet well defined. The benefit of adjuvant chemotherapy and radiotherapy (RT), given as single modalities or sequentially, is still unclear. Furthermore, insight into the predictive and prognostic impact of various biomarkers is surging.

Objectives: To compare postoperative sequential RT and chemotherapy to RT alone in adults with newly diagnosed AO or mixed AOA. To evaluate the predictive and prognostic impact of the following biomarkers: codeletion of chromosomes 1p and 19q, O(6)-methylguanine-DNA methyltransferase (MGMT) promotor methylation and isocitrate dehydrogenase (IDH)-1 and -2 mutations.

Search methods: We searched the Cochrane Central Register for Controlled Trials (CENTRAL, Issue 1, 2014), MEDLINE (2006 to March week 2, 2014) and EMBASE (2006 to week 11, 2014). We scanned reference lists from relevant studies for any additional articles.

Selection criteria: We included randomized controlled trials (RCTs) of adults with AO, AOA or anaplastic astrocytoma (AA) comparing adjuvant treatment of chemotherapy, RT, or sequential chemotherapy and RT. We excluded no specific chemotherapy regimens.

Data collection and analysis: We critically appraised and extracted data from relevant studies. Based on the differences in participant selection with respect to the definition of AO (two versus three high-risk anaplastic features), the inclusion of AA and sequence of treatment (RT and chemotherapy), we could not consider the results from the three RCTs for meta-analysis.

Main results: Three RCTs, with 931 participants, tested different neoadjuvant treatments: RT alone; sequential RT and procarbazine, lomustine and vincristine (PCV) chemotherapy; PCV chemotherapy alone; and temozolomide chemotherapy alone. None of the studies blinded participants or personnel, and, therefore, are considered at high risk of performance and detection bias. The studies were otherwise at low risk of bias. One study, the European Organisation for Research and Treatment of Cancer (EORTC) trial, demonstrated a statistically significant overall survival (OS) benefit for RT plus PCV, with a median OS of 3.5 years compared with 2.6 years in the RT alone arm (P value = 0.018). This result was reported 10 years after the conclusion of the enrolment, and was not apparent in the original 2008 Cochrane review. Furthermore, with retrospective evaluation of biomarkers, codeletion of complete chromosome arms 1p and 19q and IDH-1 or -2 mutation were independent prognostic factors for OS in two of the RCTs (Radiation Therapy Oncology Group (RTOG) and EORTC), and were predictive for OS in one trial (RTOG). The third trial (NOA-04) evaluated these biomarkers prospectively and found them prognostic for progression-free survival.

Authors' conclusions: Early PCV, either before or after RT, appears to improve OS of participants with AO or AOA. Use of biomarkers including codeletion of chromosomes 1p and 19q with or without IDH-1 or -2 mutation identify a subset of people with increased sensitivity to combined PCV and RT. The important role of biomarkers was supported in all of the RCTs examined, and prospective evaluation should be undertaken in future studies. However, PCV was associated with significant grade 3 and 4 toxicities, and whether temozolomide can be substituted for this remains unclear.

PubMed Disclaimer

Conflict of interest statement

None.

Update of

References

References to studies included in this review

Cairncross 2006 {published data only}
    1. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology 2006; 24(18):2707-14. - PubMed
    1. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology 2013; 31:337-43. - PMC - PubMed
    1. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology 2014; 32(8):783-90. - PMC - PubMed
    1. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology 2008; 18:360-9. - PMC - PubMed
NOA‐04 2009 {published data only}
    1. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology 2009; 27(35):5874-80. - PubMed
van den Bent 2006 {published data only}
    1. Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology 2011; 103:221-30. - PMC - PubMed
    1. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology 2009; 11:737-46. - PMC - PubMed
    1. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology 2007; 25:5731-37. - PubMed
    1. Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoorn M, et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer 2011; 117:3014-26. - PubMed
    1. den Ben MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology 2013; 31:344-50. - PubMed

Additional references

Balss 2008
    1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica 2008; 116(6):597-602. - PubMed
Boots‐Sprenger 2013
    1. Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Modern Pathology 2013; 26(7):922-9. - PubMed
Cairncross 1994
    1. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1994; 12(10):2013-21. - PubMed
Cairncross 1998
    1. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute 1998; 90(19):1473-9. - PubMed
Camelo‐Piragua 2010
    1. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathologica 2010; 119:509-11. - PMC - PubMed
CBTRUS 2009
    1. Central Brain Tumor Registry of the United States. Primary brain tumors in the United States statistical report, 2005-2009. Neuro-oncology 2009; 14 Suppl 5:v1-49. - PMC - PubMed
Hartmann 2009
    1. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica 2009; 118:469-74. - PubMed
Higgins 2011
    1. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928. - PMC - PubMed
Ichimura 2009
    1. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009; 11:341-7. - PMC - PubMed
Kloosterhof 2011
    1. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? The lancet oncology 2011; 12:83-91. - PubMed
Kouwenhoven 2009
    1. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology 2009; 11:737-46. - PMC - PubMed
Laffaire 2011
    1. Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, Reyniès A, et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-oncology 2011; 13:84-98. - PMC - PubMed
Lassman 2011
    1. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology 2011; 13:649-59. - PMC - PubMed
Li 2012
    1. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-oncology 2012; 14:109-16. - PMC - PubMed
NCT00626990
    1. NCT00626990. Radiation therapy with or without temozolomide in treating patients with anaplastic glioma. clinicaltrials.gov/ct2/show/NCT00626990 (accessed 13 May 2014).
NCT00887146
    1. NCT00887146. Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma. clinicaltrials.gov/show/NCT00887146 (accessed 13 May 2014).
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998; 17(24):2815-34. - PubMed
Parsons 2008
    1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-12. - PMC - PubMed
Smith 2000
    1. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Journal of Clinical Oncology 2000; 18(3):636-45. - PubMed
Sonoda 2009
    1. Sonoda Y, Kumabe T, Nakamura T, Kanamori M, Yamashita Y, Suzuki H, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science 2009; 100:1996-8. - PMC - PubMed
Stupp 2005
    1. Stupp R, Mason WP, den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005; 352:987-96. - PubMed
van den Bent 2003
    1. den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97:1276-84. - PubMed
Watanabe 2009
    1. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. American Journal of Pathology 2009; 174:1149-53. - PMC - PubMed
Yan 2009
    1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 2009; 360:765-73. - PMC - PubMed

References to other published versions of this review

Quon 2008
    1. Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD007104] - DOI - PubMed

Publication types